Lawmakers seek marketing info

Share this article:
The House Committee on Oversight and Government Reform has asked five drug and medical device companies for documents on their marketing practices. The requests are part of the subcommittee’s heightened oversight of marketing in the drug and device industry.

Letters were sent to Eli Lilly, AstraZeneca, Boston Scientific, Cordis and Cephalon.

The letters ask for information on clinical trials, compensation to experts, explanations for why some unpublished studies were not published, any marketing department support for studies, information given to company and consultant sales personnel, and other items.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...